Lately, the investment community has singled out the bioinformatics sector as a safe bet — a haven of almost-certain growth in the otherwise risky IT playing field. This budding investor interest has brought with it an accompaniment of services: increased analyst coverage, focused market reports, and dedicated legal practices have sprung up around the promise of the growing sector. But the latest entry to this bioinformatics service industry, the Adrenaline Group, said it doesn’t plan to cater solely to the investor side of the equation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.